Actelion submits first part of bosentan NDA

Actelion (SWX:ATLN) submitted to the FDA the initial sections of its NDA for bosentan ( Ro 47-0203), an oral endothelin receptor antagonist, to treat pulmonary hypertension. ATLN expects to submit the...